ATRC News and Press, AtriCure Inc. From 04/11/23

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release first quarter 2023 financial results on Tuesday, May 2, ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 22nd Annual Needham Vi...

2023-03-21 11:06:46 ET The following slide deck was published by AtriCure, Inc. in conjunction with this event. For further details see: AtriCure (ATRC) Presents At Oppenheimer 33rd Annual Health Conference - Slideshow

AtriCure, Inc. (ATRC) Q4 2022 Earnings Conference Call February 21, 2023, 16:30 PM ET Company Participants Marissa Bych - Gilmartin Group, Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference...

AtriCure press release ( NASDAQ: ATRC ): Q4 GAAP EPS of -$0.09 beats by $0.09 . Revenue of $88M (+20.2% Y/Y) beats by $0.1M . Adjusted EBITDA was positive for the fourth quarter 2022 at $6.0 million, compared to negative $2.1 million for fourth quarter of 2021. Adjus...

2022 Worldwide revenue of $330.4 million – an increase of 20.4% year over year 2022 U.S. revenue of $277.2 million – an increase of 21.0% year over year 2022 International revenue of $53.2 million – an increase of 17.7% in 2022 AtriCure, Inc. ( Nasdaq:...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Oppenheimer 33 rd Annual Healthc...

Summary Cryoport has significantly underperformed the broader market over the past several months, largely due to poor earnings and cash flows. The company has excess cash on its books, but this doesn't make it a great prospect when you consider its continued profitability issues. A...

Trial will evaluate the safety and effectiveness of the AtriCure AtriClip ® Left Atrial Appendage Exclusion System for stroke prevention in cardiac surgery patients AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibr...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2022 financial results ...